Beyond the thesis, first-time biotech funds must explicitly align with LPs on the 6-to-9-year journey from seed to exit. Daniel Fero stresses finding LPs who understand their capital will be locked up for a long duration, unlike in crossover funds with shorter horizons. This "psychological fit" on capital flow expectations is crucial for a stable fund.

The biggest venture outcomes often take 8-10 years or more to mature. Instead of optimizing for quick IRR, early-stage VCs should embrace long holding periods. This "duration" is a feature that allows for massive value creation and aligns with building truly transformative companies, prioritizing multiples over short-term gains.

A hedge fund's focus on yearly performance incentivizes betting on short-term catalysts, like clinical data events. In contrast, a venture capital fund's typical 10-year lockup period allows it to ignore market cycles and underwrite the best science for a long-term outcome.

Unlike software, hard tech involves long scale-up timelines and high capital costs. Founders must specifically seek the small subset of investors and partners who understand the market context and have the risk appetite for massive, world-changing opportunities, rather than trying to appeal to all VCs.

Zipline's journey highlights a mismatch between standard VC fund timelines (10-12 years) and the longer development cycles of "real-world tech" like robotics. Founders in these spaces must be prepared for a 15-20 year journey and communicate this reality to investors from the start.

To vet ambitious ideas like self-sailing cargo ships, first ask if they are an inevitable part of the world in 100 years. This filters for true long-term value. If the answer is yes, the next strategic challenge is to compress that timeline and build it within a 10-year venture cycle.

VCs at the highest level don't just write checks; they fundamentally reset a founder's aspirations. By placing a startup in the lineage of giants like Google and Oracle, they shift the goal from building a big business to creating a generational company.

Shkreli argues that revolutionary hardware ventures require exceptionally long time horizons, making traditional VCs unsuitable partners due to their fund cycles. He suggests targeting corporate investors who understand and can stomach a 15-20 year development runway.

De-extinction company Colossal Biosciences is seeking funding at a massive $20-30B valuation. Its success demonstrates that a powerful story that captures the public's imagination can attract significant investment, even when it falls outside the traditional biopharma framework and faces skepticism about its business model.